Compare CABA & RMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABA | RMR |
|---|---|---|
| Founded | 2017 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.7M | 253.9M |
| IPO Year | 2019 | N/A |
| Metric | CABA | RMR |
|---|---|---|
| Price | $2.31 | $16.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $14.57 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 4.2M | 193.8K |
| Earning Date | 11-10-2025 | 02-04-2026 |
| Dividend Yield | N/A | ★ 11.49% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.36 |
| Revenue | N/A | ★ $157,772,000.00 |
| Revenue This Year | N/A | $251.56 |
| Revenue Next Year | N/A | $3.20 |
| P/E Ratio | ★ N/A | $11.50 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.99 | $13.48 |
| 52 Week High | $3.67 | $19.24 |
| Indicator | CABA | RMR |
|---|---|---|
| Relative Strength Index (RSI) | 44.42 | 65.04 |
| Support Level | $2.42 | $14.97 |
| Resistance Level | $2.61 | $15.50 |
| Average True Range (ATR) | 0.25 | 0.40 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 20.38 | 97.61 |
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
The RMR Group Inc is a holding company that conducts its business through its subsidiary, which is an alternative asset management company that invests in real estate and manages real estate-related businesses. Its business consists of providing management services to publicly owned real estate investment trusts, or REITs, and real estate-related operating companies. It also provides management services to real estate securities mutual funds and commercial real estate finance companies. The company's operating segment is RMR LLC and All Other Operations. The RMR Group derives its revenue from providing business and property management services as well as advisory and other services.